Advancing Medicine Is In Daniel MacArthur’s DNA

When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.
Daniel MacArthur with Melbourne scientist and assistant professor Misty Jenkins. Both will be speaking at the Sohn Hearts & Minds conference in Sydney.

Glenda Korporaal

Advancing Medicine Is In Daniel MacArthur’s DNA

November 15, 2023
When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.
Read Transcript

When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.

Based in Boston as co-director of the Medical and Population Genomics Program at the Broad Institute for Mendelian Genomics at MIT and Harvard, his work in the US had involved using new genomic technologies to help predict and diagnose diseases.

It included overseeing a team that built one of the largest genetic data bases ever assembled, collecting data from more than 140,000 people.

MacArthur saw the new centre – a joint initiative of the Garvan Institute in Sydney and the Murdoch Children’s Institute in Melbourne – as the chance to bring his years of expertise in genomic medicine back to Australia.

“The centre’s focus is applying a lot of the lessons we had learned in the early days in building the field of genomic medicine, particularly in places like the US and the UK, and applying it in the context of the Australian community,” MacArthur says.

MacArthur will outline his ­vision for genomic medicine in Australia at the Sohn Hearts & Mind Conference in Sydney on Friday.

The conference, which features top fund managers from Australia and around the world giving their best stock tips, has raised $60m for medical research in Australia since it began in 2016.

This is the first year that The Centre for Population Genomics, which has been funded from a combination of government grants and philanthropy, will receive funding from the conference.

MacArthur says his aim at the conference will be to explain the potential of the developing field of genomic medicine in Australia, adding that it is “an exciting time for the field”.

While genetics involves the study of how a person’s genes can cause a disease or an illness, the newer field of genomics involves the study of all of a person’s genes – the genome – looking at how the combination of genetic factors and environment can cause disease.

“All conditions, including the big killers like heart disease and cancer, have a contribution from both our DNA and the environment,” MacArthur says.

“If we can better understand the DNA component, it makes it a lot easier for us to identify the ­people who are most at risk of those conditions and give them the information they might need to make lifestyle changes, and also to think about how we might be able to develop therapies which could reduce the risk of those ­conditions.”

MacArthur’s work has included understanding the basis of certain rare genetic disorders, which can cause diseases such as muscular dystrophy and which particularly affect children.

Working in Boston, he oversaw a program that sequenced and analysed genomic data from more than 10,000 people from families with rare diseases – work that contributed to the discovery of more than 100 new rare disease genes.

‘We can now think about making precise changes to someone’s DNA’

Daniel MacArthur, genomic scientist

But Australia’s racial mix – which includes many people from Asia, the Middle East and South Pacific – is very different to that in the European nations that have provided the basis for a lot of genomic medicine research to date.

“My driving purpose with the centre is thinking about ways we can make sure the benefit of new technologies is available to all Australians, regardless of their background,” MacArthur said.

“We are focused on working directly with communities to build up a better picture of the patterns of genetic variation that exist within the Australian community and use it to predict and build better tools for the diagnosis, prediction and treatment of ­disease.”

When MacArthur left Australia, in 2007, after completing his PhD in human genetics at the University of Sydney, there was little work being done in the field of genomics. “But since then, there has been a huge amount of work to build up the infrastructure and the approaches to it,” he says.

“The centre, is a partnership between two different institutions in Sydney and Melbourne, is a new approach to bringing together genetic information at a very large scale in a way which can benefit Australian communities, not just the ones that are already being studied in other places around the world.”

MacArthur is based in Sydney and oversees a team that has members in Sydney, Melbourne and New Zealand.

One of his goals is to build a ­genomic data base from about 10,000 people from specific groups in Australia, including people from the Pacific, Southeast Asia, the Middle East and East ­Africa, to help study diseases in those populations.

“More than a quarter of Australian citizens were born overseas and more than half have at least one parent born overseas,” he says. “It is essential we have a genetic resource which is fit for purpose in our own country, which captures the full spectrum of diversity which exists here.”

He says the study of genomic medicine is now taking off as a result of a combination of factors including a sharp drop in the cost of the technology involved.

“The first human genome, which took about 10 years to ­sequence by a team of scientists around the world, was released in 2003, and took about $3bn to generate,” he says. “These days we can sequence a genome for less than $1000. It takes a week and is more accurate than the genome we generated back in 2003.

“It is an almost unprecedented drop in the cost of the technology which allows us to think about ­applying genomics to so many people around the world and so many patients.”

Big advances in data science such as cloud computing and the broader availability of artificial intelligence have also allowed for much easier processing of huge amounts of data.

“These technologies are now the key factor in our ability to make sense of the data and use it to diagnose, predict and treat disease,” MacArthur says.

There have also been big advances in the drugs and therapeutics available to treat diseases.

“It means we can now think about making precise changes to someone’s DNA in ways which can help cure their condition, or even potentially prevent a condition that they might go on to develop in future,” MacArthur says.

The Australian is a media partner of Sohn Hearts & Minds. You can watch Prof Daniel MacArthur's presentation from the event here.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.

Based in Boston as co-director of the Medical and Population Genomics Program at the Broad Institute for Mendelian Genomics at MIT and Harvard, his work in the US had involved using new genomic technologies to help predict and diagnose diseases.

It included overseeing a team that built one of the largest genetic data bases ever assembled, collecting data from more than 140,000 people.

MacArthur saw the new centre – a joint initiative of the Garvan Institute in Sydney and the Murdoch Children’s Institute in Melbourne – as the chance to bring his years of expertise in genomic medicine back to Australia.

“The centre’s focus is applying a lot of the lessons we had learned in the early days in building the field of genomic medicine, particularly in places like the US and the UK, and applying it in the context of the Australian community,” MacArthur says.

MacArthur will outline his ­vision for genomic medicine in Australia at the Sohn Hearts & Mind Conference in Sydney on Friday.

The conference, which features top fund managers from Australia and around the world giving their best stock tips, has raised $60m for medical research in Australia since it began in 2016.

This is the first year that The Centre for Population Genomics, which has been funded from a combination of government grants and philanthropy, will receive funding from the conference.

MacArthur says his aim at the conference will be to explain the potential of the developing field of genomic medicine in Australia, adding that it is “an exciting time for the field”.

While genetics involves the study of how a person’s genes can cause a disease or an illness, the newer field of genomics involves the study of all of a person’s genes – the genome – looking at how the combination of genetic factors and environment can cause disease.

“All conditions, including the big killers like heart disease and cancer, have a contribution from both our DNA and the environment,” MacArthur says.

“If we can better understand the DNA component, it makes it a lot easier for us to identify the ­people who are most at risk of those conditions and give them the information they might need to make lifestyle changes, and also to think about how we might be able to develop therapies which could reduce the risk of those ­conditions.”

MacArthur’s work has included understanding the basis of certain rare genetic disorders, which can cause diseases such as muscular dystrophy and which particularly affect children.

Working in Boston, he oversaw a program that sequenced and analysed genomic data from more than 10,000 people from families with rare diseases – work that contributed to the discovery of more than 100 new rare disease genes.

‘We can now think about making precise changes to someone’s DNA’

Daniel MacArthur, genomic scientist

But Australia’s racial mix – which includes many people from Asia, the Middle East and South Pacific – is very different to that in the European nations that have provided the basis for a lot of genomic medicine research to date.

“My driving purpose with the centre is thinking about ways we can make sure the benefit of new technologies is available to all Australians, regardless of their background,” MacArthur said.

“We are focused on working directly with communities to build up a better picture of the patterns of genetic variation that exist within the Australian community and use it to predict and build better tools for the diagnosis, prediction and treatment of ­disease.”

When MacArthur left Australia, in 2007, after completing his PhD in human genetics at the University of Sydney, there was little work being done in the field of genomics. “But since then, there has been a huge amount of work to build up the infrastructure and the approaches to it,” he says.

“The centre, is a partnership between two different institutions in Sydney and Melbourne, is a new approach to bringing together genetic information at a very large scale in a way which can benefit Australian communities, not just the ones that are already being studied in other places around the world.”

MacArthur is based in Sydney and oversees a team that has members in Sydney, Melbourne and New Zealand.

One of his goals is to build a ­genomic data base from about 10,000 people from specific groups in Australia, including people from the Pacific, Southeast Asia, the Middle East and East ­Africa, to help study diseases in those populations.

“More than a quarter of Australian citizens were born overseas and more than half have at least one parent born overseas,” he says. “It is essential we have a genetic resource which is fit for purpose in our own country, which captures the full spectrum of diversity which exists here.”

He says the study of genomic medicine is now taking off as a result of a combination of factors including a sharp drop in the cost of the technology involved.

“The first human genome, which took about 10 years to ­sequence by a team of scientists around the world, was released in 2003, and took about $3bn to generate,” he says. “These days we can sequence a genome for less than $1000. It takes a week and is more accurate than the genome we generated back in 2003.

“It is an almost unprecedented drop in the cost of the technology which allows us to think about ­applying genomics to so many people around the world and so many patients.”

Big advances in data science such as cloud computing and the broader availability of artificial intelligence have also allowed for much easier processing of huge amounts of data.

“These technologies are now the key factor in our ability to make sense of the data and use it to diagnose, predict and treat disease,” MacArthur says.

There have also been big advances in the drugs and therapeutics available to treat diseases.

“It means we can now think about making precise changes to someone’s DNA in ways which can help cure their condition, or even potentially prevent a condition that they might go on to develop in future,” MacArthur says.

The Australian is a media partner of Sohn Hearts & Minds. You can watch Prof Daniel MacArthur's presentation from the event here.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on Nov 15, 2023. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
September 5, 2024

Why Howard Marks says you’re making a big mistake

Howard Marks says investors must ignore manic depressive markets and focus on the bigger picture. Rates will be higher for longer and that will bring pain – and opportunity.

Read More
July 21, 2024

Investors ‘comfortable’ about a Trump presidency, despite volatility

Economists and market experts say the outcome of the US presidential election has been largely priced in by investors as softening inflation helps to buoy sharemarkets both globally and locally.

Read More
Qiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar ColmanQiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar ColmanQiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar ColmanQiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar Colman
May 28, 2024

The AI bulls are sticking to Nvidia despite 600pc share price rally

Nvidia’s quarterly earnings once again exceeded analysts’ expectations and Portfolio Manager, Qiao Ma of Munro Partners says the rise is “nowhere close to being over”.

Read More
Munro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke MeitzelMunro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke MeitzelMunro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke MeitzelMunro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke Meitzel
February 15, 2024

Hedge fund Munro says Nvidia, Microsoft have more to run

Kieran Moore is portfolio manager of Munro Partners Global Growth Fund. The Melbourne-based hedge fund oversees $4.3 billion in assets.

Read More
January 24, 2024

How To Master The Art Of Winning The Room

Jonathan Pease, the creative director behind the Sohn Hearts & Minds Conference and author of the book, Winning the Room, recently sat down for a chat with Mark Bouris on Straight Talk.

Read More
2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 
January 19, 2024

Best funds of 2023 stick with bitcoin, big tech bets

Some of the best performing funds of 2023 are holding firm on bitcoin and mega-cap tech stock picks that made them big money last year.

Read More
November 19, 2023

Equity Mates review the stocks pitched at the Sohn Hearts & Minds Conference

Bryce and Ren of Equity Mates attended the Sohn Hearts & Minds Conference and reviewed the stocks pitched by our new 2023 Conference Fund Managers.

Read More
Ark Invest CEO Cathie Wood remains as big-picture as ever. Picture: David RoweArk Invest CEO Cathie Wood remains as big-picture as ever. Picture: David RoweArk Invest CEO Cathie Wood remains as big-picture as ever. Picture: David RoweArk Invest CEO Cathie Wood remains as big-picture as ever. Picture: David Rowe
November 17, 2023

‘I Know It Sounds Crazy’: Cathie Wood’s Next Big Idea

Speaking from Ark’s headquarters in Florida ahead of her appearance at the Sohn Hearts & Minds Conference on Friday, Wood says she believes disinflation is now just around the corner in the US.

Read More
ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.
November 17, 2023

ARK Founder Wood Backs Bitcoin, Banking On Spot ETF Approval

Tech investment guru Cathie Wood is still a big believer in bitcoin, so it was fitting that she chose Grayscale Bitcoin Trust as her stock pick for the 2023 Sohn Hearts & Minds Investment Leaders Conference.

Read More
IFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee NowytargerIFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee NowytargerIFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee NowytargerIFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee Nowytarger
November 17, 2023

Hot Stocks To Ride The Next Healthcare Trends

Healthcare stocks – from sleep apnoea giant ResMed, to cancer diagnostic biotech Telix Pharmaceuticals – were recommended at the Sohn Hearts & Minds Investment Leaders Conference on Friday.

Read More
November 17, 2023

How Daniel Loeb, The Real Bobby Axelrod, Made His Wall Street Billions

When Damian Lewis, the actor who plays the ruthless hedge fund boss in the drama series Billions was looking for inspiration, he sat down with Daniel Loeb.

Read More
November 17, 2023

The 12 Hottest Stock Tips From This Year’s Sohn Experts

It might be time to look beyond big names. That was the message from top fund managers, company founders and super funds at the Sohn Hearts & Minds.

Read More
Azora Capital founder Ravi Chopra. Picture: Renee NowytargerAzora Capital founder Ravi Chopra. Picture: Renee NowytargerAzora Capital founder Ravi Chopra. Picture: Renee NowytargerAzora Capital founder Ravi Chopra. Picture: Renee Nowytarger
November 17, 2023

Webster Financial ‘Avoided The Mistakes Of US Bank Failures’

The US financial sector is not without its problems but Ravi Chopra backs Webster Financial Corporation as his stock pick for the 2023 Sohn Hearts & Minds Investment Leaders Conference.

Read More
November 17, 2023

Why Stock Picker Cathie Wood Of ARK Can’t Stand Google

The world’s highest-profile tech investor, Cathie Wood, might be bruised but she is certainly bullish. Nor is she holding back.

Read More
Munro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee NowytargerMunro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee NowytargerMunro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee NowytargerMunro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee Nowytarger
November 17, 2023

Wise Share Price Could Rise 50pc By 2025, Says Munro Partners

Global growth fund manager Munro has about $4.3bn in funds under management across four global funds, and usually invests in companies that are poised to win from massive structural change.

Read More